Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breath analysis enables prediction of atherosclerotic cardiovascular disease risk.

The American journal of the medical sciences·2026
Same author

Epigenetic brain reprogramming rejuvenates neuro-immune circuits to reverse Alzheimer's disease pathology and systemic bone loss.

Journal of neuroinflammation·2026
Same author

Association of mitochondrial genome variants with Alzheimer's disease in a Chinese population.

Journal of Alzheimer's disease : JAD·2026
Same author

Guanidinoacetic acid improves flesh quality associated with collagen synthesis and nucleotide metabolism in gibel carp CAS V (<i>Carassius gibelio</i>, CAS V).

Animal nutrition (Zhongguo xu mu shou yi xue hui)·2026
Same author

Interferon-tau regulates the PGE<sub>2</sub>/PGF<sub>2α</sub> ratio via ISG15 in the goat corpus luteum during early pregnancy.

Theriogenology·2026
Same author

Apolipoprotein E4 and synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic implications.

Ageing research reviews·2026
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Haokun Liu1, Weiwei Zhang1, Keying Fang1

  • 1Xiangya Hospital, Central South University, Changsha, Hunan, China.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

Lecanemab treatment for Alzheimer's disease (AD) in China shows safety and potential for improving glymphatic function, as evidenced by 7.0T MRI and DTI-ALPS imaging. Long-term efficacy requires further study.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Area of Science:

  • Neurology
  • Radiology
  • Pharmacology

Background:

  • Lecanemab's effectiveness in early Alzheimer's disease (AD) is established, but validation in China is limited.
  • Traditional evaluation methods for AD lack precision, especially in brain imaging.
  • Advanced imaging techniques like 7.0-tesla ultra-high-field MRI with SWI and DTI-ALPS can precisely detect microbleeds and assess glymphatic function.

Purpose of the Study:

  • To assess the efficacy and safety of lecanemab in Chinese AD patients.
  • To evaluate lecanemab's impact on brain microstructure and amyloid-β (Aβ) clearance.
  • To investigate the role of advanced MRI techniques in monitoring treatment response.

Main Methods:

  • 27 AD patients received lecanemab treatment starting June 28, 2024.
  • 7.0T Siemens Terra MRI with SWI and DTI sequences were used for pre- and post-treatment imaging.
  • Cognitive function was assessed using MMSE and MoCA; glymphatic function was evaluated using the DTI-ALPS index.

Main Results:

  • Lecanemab was generally safe, with only mild flu-like symptoms in 7.4% of patients.
  • No new microhemorrhages or ARIA-E/ARIA-H were detected using 7.0T MRI SWI.
  • A statistically significant increase in the left DTI-ALPS index indicated improved glymphatic function post-treatment (p=0.024).

Conclusions:

  • Lecanemab treatment is generally safe for AD patients in Hunan, China, but long-term efficacy needs further research.
  • 7.0T MRI SWI is a valuable tool for monitoring microbleeds and enhancing safety surveillance.
  • DTI-ALPS shows promise as an imaging biomarker for assessing lecanemab's treatment efficacy by reflecting glymphatic function improvements.